As reported by the authors, the absence of concomitant cardiovascular or antidiabetic drugs in 75% of all cases could suggest that pre-existing cardiac disorders or cardiovascular risk factors would not predispose patients to develop immune checkpoint inhibitor-associated myocarditis. A more precise analysis of potential predisposing conditions could have been done by capturing comorbidities, such as we have done in a study that we have just finished and submitted for peer-review.
Reporting of immune checkpoint inhibitor-associated myocarditis
Magro, L;
2018-01-01
Abstract
As reported by the authors, the absence of concomitant cardiovascular or antidiabetic drugs in 75% of all cases could suggest that pre-existing cardiac disorders or cardiovascular risk factors would not predispose patients to develop immune checkpoint inhibitor-associated myocarditis. A more precise analysis of potential predisposing conditions could have been done by capturing comorbidities, such as we have done in a study that we have just finished and submitted for peer-review.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
